EBS

Emergent BioSolutions Inc. (EBS) | Rumor.io

Emergent BioSolutions

EBS

Attention (50-day avg)0%

Attention rank (50-day avg)#1,954

Bullish sentiment (50-day avg)51%

Price to earnings ratio8.59

Market capitalization351.7M

Earnings per share-3.41

Dividend yield (TTM)—

Revenue (annual)705.2M

Net income (annual)52.6M

Social

What share of all stock conversation is about EBS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% -0.01

Aug 12

The company's biodefense products, particularly its anthrax franchise, are its most defining and relevant product line, with a significant revenue contribution.
The company's MCM products have been the larger revenue contributor in recent periods, with COMMERCIAL products, such as Narcan, being a significant secondary line but facing generic competition and declining sales.
The global biodefense market is projected to grow significantly, with spending increasing globally, which could have a positive impact on the company's stock price.

Generated by AI

Sentiment

Of the messages about EBS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -80	59.18% +10.98	70.25% -3.85
Bearish	—	100% +80	40.82% -10.98	29.75% +3.85

Bullish· Feb 27

$EBS is undervalued, with a promising future and potential for exceeding guidance, making it a good buy in the $8.45 to $8.50 range.
The company is a solid cash flow machine, with a 50 million buyback program and the potential to pay off remaining debt, making it an attractive long-term investment.
Emergent BioSolutions has a history of conservative guidance, so increased guidance is expected every 3 months, and the company's real problem is the customer, making diversification away from the customer crucial.

Bearish· Aug 5

$EBS has dropped 39% YTD, with a significant loss due to impairments.
Emergent BioSolutions Inc. is struggling to deliver original ideas, with management content collecting paychecks and screwing shareholders.
The company's stock has experienced a significant gap down, with a reduced position by 2/3 within the price range of $8-9.

Generated by AI

Topics

Of the messages about EBS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	39.45%
Macro	0%	0%	0%	9.06%
Technical Analysis	0%	0%	0%	16.22%
Earnings	0%	0%	0%	24.17%
Analysts	0%	0%	0%	4.88%
Controversies	0%	0%	0%	6.22%

Earnings· May 2

Emergent BioSolutions Inc. (EBS) reported a 168% earnings per share (EPS) beat in its first quarter 2024 earnings, with total revenues of $300.4 million.
The company's stock is starting to re-rate to its fair value of $15-$20, with a strong buy recommendation and a share price target of $15-$20.
The new experienced CEO of EBS will receive an $8 million bonus when the share price reaches $15, further incentivizing the stock's upward momentum.

Analysts· Nov 11

Analysts have raised the price target for EBS to $60, representing a 400% upside from the current share price of $12.
The price target increase is based on Emergent BioSolutions' (EBS) FY25 earnings per share (EPS) of $4 and price-to-earnings (PE) ratio of 15.
Analysts consider EBS a Strong Buy due to the massive 1270% earnings beat in Q3 2024, as highlighted in a short video overview.

Announcements· Aug 30

The FDA has approved Emergent BioSolutions' ACAM2000 smallpox vaccine for use in people at high risk for mpox infection, expanding its use beyond smallpox.
The approval comes amid an ongoing mpox outbreak and follows the WHO's declaration of a global public health emergency, with Emergent planning to donate 50,000 doses to support global health efforts.
The expanded indication for ACAM2000 is seen as a key development in combating mpox, with Emergent's CEO stating that the company is poised to support the global response needed to address the outbreak.

Controversies· Apr 21

The FDA has cited Emergent BioSolutions for multiple deficiencies at its Baltimore manufacturing facility, including contaminated materials and unsanitary conditions.
The facility was found to have contaminated materials from AstraZeneca's vaccine, resulting in millions of Johnson & Johnson doses being ruined and production being moved elsewhere.
The FDA's inspection report described dirty facilities, potential contamination, and inadequate employee training, with some employees carrying unsealed medical waste and working in areas with cracked containers and peeling paint.

Technical Analysis· Aug 30

$EBS has confirmed a potential bottom, with a trend change expected soon, and is nearing its 52-week high.
The stock has shown a strong close on the 4-hour candle, and is looking to test the 11.5-12.5 zone, with key support at 8.5-9.
The 5-minute 13ema is acting as resistance, and a volume-weighted average price crossover has occurred, indicating a potential gain of 15.6% with a float of 49.6M.

Generated by AI

Community

Of the messages about EBS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	62.88%	82.99%
Newcomers	0%	0%	37.12%	17.01%

Regulars· Aug 12

The regulars are focused on the potential bankruptcy of Emergent BioSolutions Inc. due to its critical role in biodefense, and the risks this poses to global security.
The company's core business is in biodefense, and the regulars are concerned that the company's earnings are being suppressed to buy stocks cheaply, and that it needs to clean up its operations and focus on its core product.
The regulars are also concerned about the company's lack of experience with retail sales, and the potential for its bioweapon business to be disrupted by competition or regulatory changes.

Newcomers· Oct 30

The newcomers are focused on the company's turnaround story, with one post highlighting a big move followed by a year-long base, and another citing a strong earnings report and raised guidance.
The newcomers are optimistic about the company's growth, with one post mentioning a 45% increase in 2026 EPS estimate and a forward PE of 10, suggesting a potential price of $17.50.
The newcomers are excited about the company's recent performance, with one post citing a 29% price increase and another highlighting a massive rebound in momentum, driven by a bullish sentiment and a strong earnings report.

Generated by AI

News

Emergent Stock: The MCM Engine Runs, But Naloxone Is Breaking Down (NYSE:EBS)

Emergent BioSolutions (EBS) outlook: MCM strength vs. NARCAN impairment and naloxone decline. Read here for a detailed investment analysis.

15d agoSeeking Alpha

Emergent BioSolutions at H.C. Wainwright conference: debt falls

15d agoInvesting.com

Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva

Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans

23d agoYahoo Finance UK

Emergent BioSolutions - Tough 2026 Outlook Warrant Rating Downgrade (NYSE:EBS)

Emergent BioSolutions (EBS) downgraded to Hold as Narcan sales slip, competition rises and debt persists; review risks, cash flow signals and act now.

23d agoSeeking Alpha

Emergent BioSolutions repurchases $75 million in senior notes

26d agoInvesting.com

Emergent BioSolutions Repurchases $75 Million of Senior Unsecured Notes Due 2028

Emergent BioSolutions (EBS) said Thursday that it has completed the repurchase of $75 million aggreg

27d agoYahoo Finance

Also Discussed

Investors talking about EBS also mention

#	Name	Attention
1	SIGA Technologies Inc.SIGA	0%new
2	CMRX - Chimerix, Inc.	——
3	GeoVax Labs, Inc.GOVX	0%+0
4	CDTX - Cidara Therapeutics, Inc.	——
5	Virax Biolabs Group Ltd.VRAX	0%+0
6	OPNT - Opiant Pharmaceuticals, Inc.	——
7	GH Research PLCGHRS	0%0
8	Root Inc.ROOT	0%0
9	PTWO - Pono Capital Two, Inc.	——
10	Alexandria Real Estate Equities, Inc.ARE	0%new

Emergent BioSolutions Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Emergent BioSolutions Inc. is a life sciences company focused on preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats. Its current business centers on medical countermeasures and specialty products, including public health protection tools used by government agencies, healthcare providers, and other institutional customers. The company’s portfolio includes commercial products, medical countermeasure products, and services, with an emphasis on areas such as opioid overdose reversal, smallpox and anthrax preparedness, and contract development and manufacturing support. Emergent BioSolutions plays a specialized role in the healthcare and biodefense markets by supplying products and services designed to support emergency readiness and public health response across the United States and international markets.

Website

Location

300 Professional Drive

Gaithersburg, MD, 20879

United States

Social

What share of all stock conversation is about EBS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% -0.01

Aug 12

The company's biodefense products, particularly its anthrax franchise, are its most defining and relevant product line, with a significant revenue contribution.
The company's MCM products have been the larger revenue contributor in recent periods, with COMMERCIAL products, such as Narcan, being a significant secondary line but facing generic competition and declining sales.
The global biodefense market is projected to grow significantly, with spending increasing globally, which could have a positive impact on the company's stock price.

Generated by AI

Sentiment

Of the messages about EBS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -80	59.18% +10.98	70.25% -3.85
Bearish	—	100% +80	40.82% -10.98	29.75% +3.85

Bullish· Feb 27

$EBS is undervalued, with a promising future and potential for exceeding guidance, making it a good buy in the $8.45 to $8.50 range.
The company is a solid cash flow machine, with a 50 million buyback program and the potential to pay off remaining debt, making it an attractive long-term investment.
Emergent BioSolutions has a history of conservative guidance, so increased guidance is expected every 3 months, and the company's real problem is the customer, making diversification away from the customer crucial.

Bearish· Aug 5

$EBS has dropped 39% YTD, with a significant loss due to impairments.
Emergent BioSolutions Inc. is struggling to deliver original ideas, with management content collecting paychecks and screwing shareholders.
The company's stock has experienced a significant gap down, with a reduced position by 2/3 within the price range of $8-9.

Generated by AI

Topics

Of the messages about EBS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	39.45%
Macro	0%	0%	0%	9.06%
Technical Analysis	0%	0%	0%	16.22%
Earnings	0%	0%	0%	24.17%
Analysts	0%	0%	0%	4.88%
Controversies	0%	0%	0%	6.22%

Earnings· May 2

Emergent BioSolutions Inc. (EBS) reported a 168% earnings per share (EPS) beat in its first quarter 2024 earnings, with total revenues of $300.4 million.
The company's stock is starting to re-rate to its fair value of $15-$20, with a strong buy recommendation and a share price target of $15-$20.
The new experienced CEO of EBS will receive an $8 million bonus when the share price reaches $15, further incentivizing the stock's upward momentum.

Analysts· Nov 11

Analysts have raised the price target for EBS to $60, representing a 400% upside from the current share price of $12.
The price target increase is based on Emergent BioSolutions' (EBS) FY25 earnings per share (EPS) of $4 and price-to-earnings (PE) ratio of 15.
Analysts consider EBS a Strong Buy due to the massive 1270% earnings beat in Q3 2024, as highlighted in a short video overview.

Announcements· Aug 30

The FDA has approved Emergent BioSolutions' ACAM2000 smallpox vaccine for use in people at high risk for mpox infection, expanding its use beyond smallpox.
The approval comes amid an ongoing mpox outbreak and follows the WHO's declaration of a global public health emergency, with Emergent planning to donate 50,000 doses to support global health efforts.
The expanded indication for ACAM2000 is seen as a key development in combating mpox, with Emergent's CEO stating that the company is poised to support the global response needed to address the outbreak.

Controversies· Apr 21

The FDA has cited Emergent BioSolutions for multiple deficiencies at its Baltimore manufacturing facility, including contaminated materials and unsanitary conditions.
The facility was found to have contaminated materials from AstraZeneca's vaccine, resulting in millions of Johnson & Johnson doses being ruined and production being moved elsewhere.
The FDA's inspection report described dirty facilities, potential contamination, and inadequate employee training, with some employees carrying unsealed medical waste and working in areas with cracked containers and peeling paint.

Technical Analysis· Aug 30

$EBS has confirmed a potential bottom, with a trend change expected soon, and is nearing its 52-week high.
The stock has shown a strong close on the 4-hour candle, and is looking to test the 11.5-12.5 zone, with key support at 8.5-9.
The 5-minute 13ema is acting as resistance, and a volume-weighted average price crossover has occurred, indicating a potential gain of 15.6% with a float of 49.6M.

Generated by AI

Community

Of the messages about EBS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	62.88%	82.99%
Newcomers	0%	0%	37.12%	17.01%

Regulars· Aug 12

The regulars are focused on the potential bankruptcy of Emergent BioSolutions Inc. due to its critical role in biodefense, and the risks this poses to global security.
The company's core business is in biodefense, and the regulars are concerned that the company's earnings are being suppressed to buy stocks cheaply, and that it needs to clean up its operations and focus on its core product.
The regulars are also concerned about the company's lack of experience with retail sales, and the potential for its bioweapon business to be disrupted by competition or regulatory changes.

Newcomers· Oct 30

The newcomers are focused on the company's turnaround story, with one post highlighting a big move followed by a year-long base, and another citing a strong earnings report and raised guidance.
The newcomers are optimistic about the company's growth, with one post mentioning a 45% increase in 2026 EPS estimate and a forward PE of 10, suggesting a potential price of $17.50.
The newcomers are excited about the company's recent performance, with one post citing a 29% price increase and another highlighting a massive rebound in momentum, driven by a bullish sentiment and a strong earnings report.

Generated by AI

Emergent BioSolutions

Social

Aug 12

Bullish· Feb 27

Bearish· Aug 5

Earnings· May 2

Analysts· Nov 11

Announcements· Aug 30

Controversies· Apr 21

Technical Analysis· Aug 30

Regulars· Aug 12

Newcomers· Oct 30

Emergent Stock: The MCM Engine Runs, But Naloxone Is Breaking Down (NYSE:EBS)

Emergent BioSolutions at H.C. Wainwright conference: debt falls

Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva

Emergent BioSolutions - Tough 2026 Outlook Warrant Rating Downgrade (NYSE:EBS)

Emergent BioSolutions repurchases $75 million in senior notes

Emergent BioSolutions Repurchases $75 Million of Senior Unsecured Notes Due 2028

Also Discussed

Emergent BioSolutions Inc.

Company Information

Location

Emergent Stock: The MCM Engine Runs, But Naloxone Is Breaking Down (NYSE:EBS)

Emergent BioSolutions at H.C. Wainwright conference: debt falls

Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva

Emergent BioSolutions - Tough 2026 Outlook Warrant Rating Downgrade (NYSE:EBS)

Emergent BioSolutions repurchases $75 million in senior notes

Emergent BioSolutions Repurchases $75 Million of Senior Unsecured Notes Due 2028

Also Discussed

Social

Aug 12

Bullish· Feb 27

Bearish· Aug 5

Earnings· May 2

Analysts· Nov 11

Announcements· Aug 30

Controversies· Apr 21

Technical Analysis· Aug 30

Regulars· Aug 12

Newcomers· Oct 30